Related to J&J and Crucell in Advanced Negotiations for €1.75B Acquisition Deal

• Pevion to Use Cevec’s Protein-Expression Technology for Infectious Disease Vaccine
  
• Nonprofit Organizations Join Forces to Evaluate Adjuvants for Pandemic Flu Vaccines
  
• Crucell Revises Terms of Pediatric and Respiratory Vaccines Deal with Sanofi Pasteur
  
• Cytos and Life Technologies Partner with A*Star in Separate Deals
  
• Medicago Wins $21M DARPA Award to Scale Up Production of Flu Vaccines
  
• NIH Bankrolls Six Centers with $100M to Characterize Human Immune Responses
  
• Emergent BioSolutions and TLV Set Up Influenza-Focused JV
  
• Okairos Obtains €16M to Advance T-Cell Vaccines for Infectious Diseases
  
• GenVec Receives Second-Year Funding from SAIC for HIV and Flu Vaccine Development
  
• Novartis Teams with Synthetic Genomics Vaccines to Develop Flu Seed Virus Banks
  
• PATH Awards Medicago Nearly $1M for Plant-Produced Flu Vaccine for Developing World
  
• Pivotal Study Finds Novartis Adjuvanted Flu Vaccine 89% Effective in Infants and Children
  
• Sinovac Wins $1.8M Chinese Flu Vaccine Contract and Gets Anflu Sanctioned in Hong Kong
  
• MedImmune Nabs Rights to IDC’s GLA Adjuvant for Infectious Disease Vaccines
  
• Japan Approves BioCryst/Shionogi Intravenous Flu Vaccine for Use in Infants and Children
  
• Protein Sciences Expands Flu Vaccine Candidate License Arrangement with UMN
  
• Biocartis Signs Assay Deal for Its MDx Platform with Janssen Pharmaceutica
  
• Inviragen and Duke-NUS Form Vaccine Partnership to Tackle Emerging Infectious Diseases
  
• LGLS Licenses Novavax’ VLP Technology to Develop Flu Vaccines for South Korea and Other Emerging Markets
  
• BARDA Doles Out $215M in Influenza Vaccine Contracts